Arterial hypertension and chronic kidney disease: consensus statement on patient management

Arterial hypertension is both the cause and the result of the progression of chronic kidney disease, which affects about 10-15% of the population worldwide and the prevalence of which is steadily increasing. As the glomerular filtration rate decreases, the blood pressure level rises respectively. Arterial hypertension (AH) and chronic kidney disease (CKD) are independent and well-known risk factors for the development of cardiovascular diseases, and their combination significantly increases the incidence and mortality from cardiovascular disease. Blood pressure control is the most important factor in slowing the progression of CKD and reducing cardiovascular risk. Currently, there is a place for discussions in the scientific community regarding the target blood pressure levels in patients suffering from CKD. Non-pharmacological methods of treatment can reduce the level of blood pressure in some cases, but do not help to achieve the target values in most of the cases. Patients with hypertension and CKD need combined drug therapy. Certain modern drugs have additional cardio- and nephroprotective properties and should be considered as the first line of therapy. A personalized approach based on evidence-based principles makes it possible to achieve blood pressure control, reducing cardiovascular risk and slowing the progression of CKD. This consensus summarizes the current literature data, as well as highlights the main approaches to the management of patients with hypertension and CKD.

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama 2007; 298: 2038–2047. https://doi.org/10.1001/jama.298.17.2038

2. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015; 88: 950–957. https://doi.org/10.1038/ki.2015.230

3. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. https://doi.org/10.1038/kisup.2012.73

4. Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021; 99: S1–S87. https://doi.org/10.1016/j.kint.2020.11.003

5. Хроническая болезнь почек (ХБП). Клинические рекомендации МЗ РФ 2021, https://cr.minzdrav.gov.ru/recomend/469_2

6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.

7. Артериальная гипертензия у взрослых. Клинические рекомендации МЗ РФ. 2020, https://cr.minzdrav.gov.ru/schema/62_2.

8. Чазова ИЕ, Жернакова ЮВ. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16:6-31. https://doi.org/10.26442/2075082X.2019.1.190179

9. Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912–1918. https://doi.org/10.1056/NEJM199212313272704

10. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063–1068. https://doi.org/10.1172/JCI118867

11. Koomans HA, Roos JC, Boer P, et al. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190–197. https://doi.org/10.1161/01.HYP.4.2.190

12. Dhaun N, Goddard J, Webb D. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17:943–955. https://doi.org/10.1681/ASN.2005121256

13. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010; 23:282–289. https://doi.org/10.1038/ajh.2009.240

14. Kim ED, Tanaka H, Ballew SH, et al. Associations between kidney disease measures and regional pulse wave velocity in a large community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2018; 72:682–690. https://doi.org/10.1053/j.ajkd.2018.04.018

15. Morony S, Flynn M, McCaffery KJ, et al. Readability of written materials for CKD patients: a systematic review. Am J Kidney Dis 2015; 65: 842–850.

16. Group SR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116. https://doi.org/10.1056/NEJMoa1511939

17. Buse JB, Group AS. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: S21–S33. https://doi.org/10.1016/j.amjcard.2007.03.003

18. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab 2012; 97: 41–48. https://doi.org/10.1210/jc.2011-1679

19. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 1996; 156: 602–611. https://doi.org/10.1001/archinte.1996.00440060016002

20. Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes, Obes Metab 2016; 18: 641–647. https://doi.org/10.1111/dom.12630

21. Чихладзе НМ. Артериальная гипертония при хронических заболеваниях почек. In: Симпоматиче- ские (вторичные) артериальные гипертонии. 2018, pp. 86–122.

22. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100: S1–S276. https://doi.org/10.1016/j.kint.2021.05.021

23. Masuda T, Nagata D. Recent advances in the management of secondary hypertension: chronic kidney disease. Hypertens Res 2020; 43: 869–875. https://doi.org/10.1038/s41440-020-0491-4

24. Leoncini G, Viazzi F, De Cosmo S, et al. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol 2020; 33: 949–963. https://doi.org/10.1007/ s40620-020-00803-3

25. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Nephrol Dial 2021; 23:9–121. https://doi.org/10.28996/2618-9801-2021-2suppl-9-121

26. Herrmann SM, Textor SC. Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens 2018; 31:139–149. https://doi.org/10.1093/ajh/hpx154

27. Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014; 32:1367–1378. https://doi.org/10.1097/HJH.0000000000000213

28. Benjamin MM, Fazel P, Filardo G, et al. Prevalence of and Risk Factors of Renal Artery Stenosis in Patients With Resistant Hypertension. Am J Cardiol 2014; 113:687–690. https://doi.org/10.1016/j.amjcard.2013.10.046

29. Dobrek L. An Outline of Renal Artery Stenosis Pathophysiology—A Narrative Review. Life 2021; 11:208. https://doi.org/10.3390/life11030208

30. Textor SC, Lerman L. Renovascular Hypertension and Ischemic Nephropathy. Am J Hypertens 2010; 23:1159–1169. https://doi.org/10.1038/ajh.2010.174

31. Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. Eur Heart J 2011; 32: 2231–2235. https://doi.org/10.1093/eurheartj/ehr056

32. Tafur JD, White CJ. Renal Artery Stenosis: When to Revascularize in 2017. Curr Probl Cardiol 2017; 42:110–135. https://doi.org/10.1016/j.cpcardiol.2017.01.004

33. Boutari C, Georgianou E, Sachinidis A, et al. Renovascular Hypertension: Novel Insights. Curr Hypertens Rev 2020; 16: 24–29. https://doi.org/10.2174/1573402115666190416153321

34. Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763–816. https://doi.org/10.1093/eurheartj/ehx095

35. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. N Engl J Med 2014; 370: 13–22. https://doi.org/10.1056/NEJMoa1310753

36. Bax L. Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function. Ann Intern Med 2009; 150:840. https://doi.org/10.7326/0003-4819-150-12-200906160-00119

37. Wheatley К, Ives N, Gray R, et al. Revascularization versus Medical Therapy for Renal-Artery Stenosis. N Engl J Med 2009; 361:1953–1962. https://doi.org/10.1056/NEJMoa0905368

38. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation; 113. Epub ahead of print March 2006. https://doi.org/10.1161/CIRCULATIONAHA.106.174526

39. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889–1916. https://doi.org/10.1210/jc.2015-4061

40. Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res 2019; 42: 293–300. https://doi.org/10.1038/s41440-018-0158-6

41. Fernández-Argüeso M, Pascual-Corrales E, Bengoa Rojano N, et al. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine 2021; 73:439–446. https://doi.org/10.1007/s12020-021-02704-2

42. Utsumi T, Kawamura K, Imamoto T, et al. Preoperative masked renal damage in Japanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol 2013; 20:685–691. https://doi.org/10.1111/iju.12029

43. Iwakura Y, Morimoto R, Kudo M, et al. Predictors of Decreasing Glomerular Filtration Rate and Prevalence of Chronic Kidney Disease After Treatment of Primary Aldosteronism: Renal Outcome of 213 Cases. J Clin Endocrinol Metab 2014; 99:1593–1598. https://doi.org/10.1210/jc.2013-2180

44. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:542–551. https://doi.org/10.2215/CJN.04750908

45. Чихладзе НМ. Феохромоцитома. In: Симпоматические (вторичные) артериальные гипертонии. 2018, p. 64.

46. Robles JF, Mercado-Asis LB, Pacak K. Pheochromocytoma: Unmasking the Chameleon. In: Endocrine Hypertension. Totowa, NJ: Humana Press, 2013, pp. 123–148. https://doi.org/10.1007/978-1-60761-548-4_7

47. Gu L-Q, Zhao L, Liu J-M, et al. Phaeochromocytoma presenting with coexisting acute renal failure, acidosis and in hyperglycaemic emergency. Br J Biomed Sci 2008; 65: 153–155. https://doi.org/10.1080/09674845.2008.11732821

48. Daher E, Fernandes G, Silva Júnior G, et al. Delayed diagnosis of pheochromocytoma associated with chronic kidney disease. Indian J Nephrol 2010; 20: 166. https://doi.org/10.4103/0971-4065.70843

49. Plouin PF, Degoulet P, Tugayé A, et al. Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author’s transl). Nouv Presse Med 1981; 10:869–72.

50. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161:355–361. https://doi.org/10.1530/EJE-09-0384

51. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99: 1915–1942. https://doi.org/10.1210/jc.2014-1498

52. Eisenhofer G, Huysmans F, Pacak K, et al. Plasma metanephrines in renal failure. Kidney Int 2005; 67: 668–677. https://doi.org/10.1111/j.1523-1755.2005.67123.x

53. Hoeldtke RD, Israel BC, Cavanaugh ST, et al. Effect of renal failure on plasma dihydroxyphenylglycol, 3-methoxy-4-hydroxyphenylglycol, and vanillylmandelic acid. Clin Chim Acta 1989; 184:195–196. https://doi.org/10.1016/0009-8981(89)90290-8

54. Pappachan JM, Raskauskiene D, Sriraman R, et al. Diagnosis and Management of Pheochromocytoma: A Practical Guide to Clinicians. Curr Hypertens Rep 2014; 16: 442. https://doi.org/10.1007/s11906-014-0442-z

55. Mannelli M, Dralle H, Lenders JW. Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art? Horm Metab Res 2012; 44:373–378. https://doi.org/10.1055/s-0032-1306275

56. Клинические рекомендации,одобренные научно-практическим Советом Минздрава РФ. Нейроэндокринные опухоли.

57. Fagundes GFC, Almeida MQ. Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas. J Endocr Soc; 6. Epub ahead of print February 2022. https://doi.org/10.1210/jendso/bvac004

58. Мельниченко ГА, Дедов ИИ, Белая ЖЕ, et al. Болезнь Иценко-Кушинга: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии 2015; 61: 55–77. https://doi.org/10.14341/probl201561255-77

59. Koch CA, Chrousos GP (eds). Endocrine Hypertension. Totowa, NJ: Humana Press, 2013. Epub ahead of print 2013. https://doi.org/10.1007/978-1-60761-548-4

60. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479–484. https://doi.org/10.1111/j.1365-2265.1994.tb02486.x

61. Magiakou MA, Mastorakos G, Zachman K, et al. Blood Pressure in Children and Adolescents with Cushing’s Syndrome before and after Surgical Cure. J Clin Endocrinol Metab 1997; 82:1734–1738. https://doi.org/10.1210/jcem.82.6.3985

62. Haentjens P, De Meirleir L, Abs R, et al. Glomerular filtration rate in patients with Cushing’s disease: a matched case–control study. Eur J Endocrinol 2005; 153: 819–829. https://doi.org/10.1530/eje.1.02040

63. Waters CB, Adams LG, Scott-Moncrieff JC, et al. Effects of Glucocorticoid Therapy on Urine Proteinto-Creatinine Ratios and Renal Morphology in Dogs. J Vet Intern Med 1997; 11:172–177. https://doi.org/10.1111/j.1939-1676.1997.tb00086.x

64. Littman MP, Robertson JL, Bovée KC. Spontaneous systemic hypertension in dogs: five cases (1981-1983). J Am Vet Med Assoc 1988; 193:486–94.

65. Ortega TM, Feldman EC, Nelson RW, et al. Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. J Am Vet Med Assoc 1996; 209:1724–9.

66. Koh, Kim, Chung, et al. Increased urinary albumin excretion in Cushing’s syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000; 52: 349–353. https://doi.org/10.1046/j.1365-2265.2000.00917.x

67. Lees GE, Brown SA, Elliott J, et al. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal). J Vet Intern Med 2005; 19: 377–85. https://doi.org/10.1892/0891-6640(2005)19377:aamopi]2.0.co;2

68. Faggiano A, Pivonello R, Melis D, et al. Nephrolithiasis in Cushing’s Disease: Prevalence, Etiopathogenesis, and Modification after Disease Cure. J Clin Endocrinol Metab 2003; 88:2076–2080. https://doi.org/10.1210/jc.2002-021494

69. Pivonello R, De Martino MC, De Leo M, et al. Cushing’s syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51:1381–1391. https://doi.org/10.1590/S0004-27302007000800025

70. Reinehr T, Kulle A, Wolters B, et al. Relationships Between 24-Hour Urinary Free Cortisol Concentrations and Metabolic Syndrome in Obese Children. J Clin Endocrinol Metab 2014; 99: 2391–2399. https://doi. org/10.1210/jc.2013-4398

71. Nieman LK, Biller BMK, Findling JW, et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526–1540. https://doi.org/10.1210/jc.2008-0125

72. Chan KCA, Lit LCW, Law ELK, et al. Diminished Urinary Free Cortisol Excretion in Patients with Moderate and Severe Renal Impairment. Clin Chem 2004; 50: 757–759. https://doi.org/10.1373/clinchem.2003.029934

73. N’Gankam V, Uehlinger D, Dick B, et al. Increased cortisol metabolites and reduced activity of 11β-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int 2002; 61: 1859–1866 https://doi.org/10.1046/j.1523-1755.2002.00308.x.

74. Letizia C, Mazzaferro S, De Ciocchis A, et al. Effects of Haemodialysis Session on Plasma Beta-Endorphin, ACTH and Cortisol in Patients with End-Stage Renal Disease. Scand J Urol Nephrol 1996; 30: 399–402. https://doi.org/10.3109/00365599609181317

75. Wallace EZ, Rosman P, Toshav N, et al. Pituitary-Adrenocortical Function in Chronic Renal Failure: Studies of Episodic Secretion of Cortisol and Dexamethasone Suppressibility*. J Clin Endocrinol Metab 1980; 50: 46–51. https://doi.org/10.1210/jcem-50-1-46

76. Manetti L, Rossi G, Grasso L, et al. Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur J Endocrinol 2013; 168: 315–321. https://doi.org/10.1530/EJE-12-0685

77. Carrasco CA, García M, Goycoolea M, et al. Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 2012; 41: 487–493. https://doi.org/10.1007/s12020-012-9597-z

78. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014; 383: 2152–2167. https://doi.org/10.1016/S0140-6736(13)61684-0

79. Parati G, Lombardi C, Hedner J, et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific a. J Hypertens 2012; 30: 633–646. https://doi.org/10.1097/HJH.0b013e328350e53b

80. Tokunou T, Ando S. Recent advances in the management of secondary hypertension—obstructive sleep apnea. Hypertens Res 2020; 43:1338–1343. https://doi.org/10.1038/s41440-020-0494-1

81. Lin C-H, Lurie RC, Lyons OD. Sleep apnea and chronic kidney disease: a state-of-the-art review. Chest 2020; 157: 673–685. https://doi.org/10.1016/j.chest.2019.09.004

82. Thenappan T. Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization. Pulmonary Circulation 2017; 7:567–568. https://doi.org/10.1177/2045893217728462

83. Navaneethan SD, Roy J, Tao K, et al. Prevalence, predictors, and outcomes of pulmonary hypertension in CKD. J Am Soc Nephrol 2016; 27:877–886. https://doi.org/10.1681/ASN.2014111111

84. Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant 2012; 27:3908–3914. https://doi.org/10.1093/ndt/gfr661

85. Selvaraj S, Shah SJ, Ommerborn MJ, et al. Pulmonary hypertension is associated with a higher risk of heart failure hospitalization and mortality in patients with chronic kidney disease: The Jackson Heart Study. Circ Hear Fail 2017; 10:e003940. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003940

86. Chakinala MM, Coyne DW, Benza RL, et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis. J Hear Lung Transplant 2018; 37: 696–705. https://doi.org/10.1016/j.healun.2017.10.028

87. Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 2012; 7:1584–1590. https://doi.org/ 10.2215/CJN.00250112

88. Goli G, Mukka R, Sairi S. Study of serum electrolytes in acute exacerbation of chronic obstructive pulmonary disease patients. Int J Res Med Sci 2016; 4: 3324–3327.

89. Kraus MA, Hamburger RJ. Sleep apnea in renal failure. In: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 1997, pp. 88–92.

90. Чазова ИЕ, Мартынюк ТВ, Валиева ЗС, et al. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский кардиологический журнал 2021; 6–43. https://doi.org/10.38109/2225-1685-2021-1-6-43

91. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2022; 43: 3618–3731. https://doi.org/10.1093/eurheartj/ehac237

92. Janda S, Shahidi N, Gin K, et al. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97: 612–622. https://doi.org/10.1136/hrt.2010.212084

93. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 2013; 84: 682–692. https://doi.org/10.1038/ki.2013.186

94. Shang W, Li Y, Ren Y, et al. Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. Int Urol Nephrol 2018; 50: 1497–1504. https://doi.org/10.1007/s11255-018-1853-6

95. Edmonston DL, Parikh KS, Rajagopal S, et al. Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis 2020; 75: 713–724. https://doi.org/10.1053/j.ajkd.2019.08.027

96. Travers A, Farber HW, Sarnak MJ. Pulmonary hypertension in chronic kidney disease. Cardiol Clin 2021; 39: 427–434. https://doi.org/10.1016/j.ccl.2021.04.004

97. Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123: 1577–1582. https://doi.org/10.1378/chest.123.5.1577

98. Tang M, Batty JA, Lin C, et al. Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis. Am J kidney Dis 2018; 72:75–83. https://doi.org/10.1053/j.ajkd.2017.11.018

99. Lam CSP, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009; 119: 2663–2670. https://doi.org/10.1161/ CIRCULATIONAHA.108.838698

100. Zlotnick DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant 2010; 25: 3090–3096. https://doi.org/10.1093/ndt/gfq141

101. Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J kidney Dis 2013; 61: 612–622. https://doi.org/10.1053/j.ajkd.2012.07.029

102. Schoenberg NC, Argula RG, Klings ES, et al. Prevalence and mortality of pulmonary hypertension in ESRD: a systematic review and meta-analysis. Lung 2020; 198: 535–545. https://doi.org/10.1007/s00408-020-00355-0

103. Imbasciati E, Gregorini G, Cabiddu G, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J kidney Dis 2007; 49:753–762. https://doi.org/10.1053/j.ajkd.2007.03.022

104. Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol 2011; 6: 2587–2598. https://doi.org/10.2215/CJN.10841210

105. Fischer MJ. Chronic kidney disease and pregnancy: maternal and fetal outcomes. Adv Chronic Kidney Dis 2007; 14: 132–145 https://doi.org/10.1053/j.ackd.2007.01.004.

106. Fischer MJ, Lehnerz SD, Hebert JR, et al. Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J kidney Dis 2004; 43:415–423. https://doi.org/10.1053/j.ajkd.2003.10.041

107. Williams D, Davison J. Chronic kidney disease in pregnancy. Bmj 2008; 336: 211–215. https://doi.org/10.1136/bmj.39406.652986.BE

108. Munkhaugen J, Vikse BE. New aspects of pre-eclampsia: lessons for the nephrologist. Nephrology Dialysis Transplantation 2009; 24: 2964–2967. https://doi.org/10.1093/ndt/gfp341

109. Cornelis T, Odutayo A, Keunen J, et al. The kidney in normal pregnancy and preeclampsia. In: Seminars in nephrology. Elsevier, 2011, pp. 4–1 4https://doi.org/10.1016/j.semnephrol.2010.10.002

110. Martinez Y V, Benett I, Lewington AJP, et al. Chronic kidney disease: summary of updated NICE guidance. bmj; 2021 Sep 6;374:n1992. Epub ahead of print 2021. https://doi.org/10.1136/bmj.n1992

111. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl; 3. Epub ahead of print 2013. https://doi.org/10.1038/kisup.2012.73

112. Piccoli GB, Cabiddu G, Attini R, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol 2015; 26: 2011–2022. https://doi.org/10.1681/ASN.2014050459

113. Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol 2019; 20: 1–43. https://doi.org/10.1186/s12882-019-1560-2

114. Приказ Минздравсоцразвития России №736 от 3 декабря 2007 г., https://minzdrav.gov.ru/documents/7780-prikaz-minzdravsotsrazvitiya-rossii-736-ot-3-dekabrya-2007-g

115. Magee LA, Von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015; 372: 407–417. https://doi.org/10.1056/NEJMoa1404595

116. Steer P, Alam MA, Wadsworth J, et al. Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. BmJ 1995; 310: 489–491. https://doi.org/10.1136/bmj.310.6978.489

117. McMullin MF, White R, Lappin T, et al. Haemoglobin during pregnancy: relationship to erythropoietin and haematinic status. Eur J Haematol 2003; 71: 44–50. https://doi.org/10.1034/j.1600-0609.2003.00085.x

118. Palacios C, De-Regil LM, Lombardo LK, et al. Vitamin D supplementation during pregnancy: Updated meta-analysis on maternal outcomes. J Steroid Biochem Mol Biol 2016; 164:148–155. https://doi.org/10.1016/j.jsbmb.2016.02.008

119. ESPN/ERA-EDTA registry annual report 2008.

120. Harambat J, van Stralen KJ, Kim JJ, et al. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27: 363–373. https://doi.org/10.1007/s00467-011-1939-1

121. Томилина НА, Андрусев АМ, Перегудова НГ, et al. Заместительная терапия терминальной хрониче- ской почечной недостаточности в Российской Федерации в 2010-2015 гг. Отчет по данным Обще- российского Регистра заместительной почечной терапии Российского диализного общества, Часть первая. Нефрология и диализ 2017; 19: 1–95.

122. Chesnaye N, Bonthuis M, Schaefer F, et al. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA–EDTA registry. Pediatr Nephrol 2014; 29: 2403–2410. https://doi.org/10.1007/s00467-014-2884-6

123. Smith JM, Stablein DM, Munoz R, et al. Contributions of the transplant registry: the 2006 annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 2007; 11: 366–373. https://doi.org/10.1111/j.1399-3046.2007.00704.x

124. Becherucci F, Lazzeri E, Lasagni L, et al. Renal progenitors and childhood: from development to disorders. Pediatr Nephrol 2014; 29: 711–719. https://doi.org/10.1007/s00467-013-2686-2

125. Becherucci F, Roperto RM, Materassi M, et al. Chronic kidney disease in children. Clin Kidney J 2016; 9: 583–591. https://doi.org/10.1093/ckj/sfw047

126. Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol 2009; 24: 431–434. https://doi.org/10.1007/s00467-008-0902-2

127. Александров АА, Кисляк ОА, Леонтьева ИВ. Клинические рекомендации. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Системные Гипертензии 2020; 17: 7–35. https://doi.org/10.26442/2075082X.2020.2.200126

128. Kavey R-EW, Allada V, Daniels SR, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients. Circulation 2006; 114: 2710–2738. https://doi.org/10.1161/CIRCULATIONAHA.106.179568

129. Haffner D, Schaefer F, Nissel R, et al. Effect of Growth Hormone Treatment on the Adult Height of Children with Chronic Renal Failure. N Engl J Med 2000; 343: 923–930. https://doi.org/10.1056/NEJM200009283431304

130. Foundation NK. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. Am J Kidney Dis 2009; 53: S11–S104. https://doi.org/10.1053/j.ajkd.2008.11.017

131. Rees L, Shaw V, Qizalbash L, et al. Delivery of a nutritional prescription by enteral tube feeding in children with chronic kidney disease stages 2–5 and on dialysis—clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2021; 36:187–204. https://doi.org/10.1007/s00467-020-04623-2

132. Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015; 65:878–888. https://doi.org/10.1053/j.ajkd.2015.01.008

133. McDonald SP, Craig JC. Long-Term Survival of Children with End-Stage Renal Disease. N Engl J Med 2004; 350: 2654–2662. https://doi.org/10.1056/NEJMoa031643

134. Craven A-MS, Hawley CM, McDonald SP, et al. Predictors of Renal Recovery in Australian and New Zealand end-Stage Renal Failure Patients Treated with Peritoneal Dialysis. Perit Dial Int 2007; 27: 184–191. https://doi.org/10.1177/089686080702700216

135. Zabetian A, Sanchez IM, Narayan KMV, et al. Global rural diabetes prevalence: A systematic review and meta-analysis covering 1990–2012. Diabetes Res Clin Pract 2014; 104: 206–213. https://doi.org/10.1016/j.diabres.2014.01.005

136. Beckett NS, Peters R, Fletcher AE, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887–1898. https://doi.org/10.1056/NEJMoa0801369

137. Bhandari S, Ives N, Brettell EA, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 2016; 31:255–261. https://doi.org/10.1093/ndt/gfv346

138. Dhaun N, MacIntyre IM, Melville V, et al. Blood Pressure–Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease. Hypertension 2009; 54: 113–119. https://doi.org/10.1161/HYPERTENSIONAHA.109.132670

139. Taylor DM, Fraser S, Dudley C, et al. Health literacy and patient outcomes in chronic kidney disease: a systematic review. Nephrol Dial Transplant 2018; 33: 1545–1558. https://doi.org/10.1093/ndt/gfx293